Compositions and methods for targeted cytokine delivery
The present disclosure encompasses compositions and methods for targeted cytokine delivery. The compositions disclosed herein comprise a cytokine linked to an NKG2D ligand or PD1 ligand and may improve immunotherapy by limiting side effects associated with immunotherapy. The present disclosure also encompasses compositions and methods for recruiting cytotoxic lymphocytes to target cells using NKG2D receptor ligands or PD1 ligands. The compositions disclosed herein comprise a NKG2D receptor ligand and a targeting molecule and may improve immunotherapy by limiting side effects associated with immunotherapy.
1. A chimeric peptide, the chimeric peptide comprising a cytokine linked to an anti-NKG2D receptor antibody, wherein the cytokine comprises the amino acid sequence set forth in SEQ ID NO:5 with or without at least one mutation selected from the group consisting of R38A, F42K and C125S, or SEQ ID NO:6.
2. The chimeric peptide of claim 1 , wherein the cytokine comprises the amino acid sequence set forth in SEQ ID NO:5 with at least one mutation selected from the group consisting of R38A, F42K and C125 S.
3. The chimeric peptide of claim 1 , wherein the cytokine comprises the amino acid sequence set forth in SEQ ID NO:6.
4. The chimeric peptide of claim 1 , wherein the anti-NKG2D receptor antibody comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs: 35 and 36; and SEQ ID NOs: 37 and 38.
5. The chimeric peptide of claim 1 , wherein the anti-NKG2D receptor antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, and SEQ ID NO: 42.
6. A method of treating a subject diagnosed with cancer comprising systemically administering to the subject a chimeric peptide, the chimeric peptide comprising a cytokine linked to an anti-NKG2D receptor antibody, wherein the cytokine comprises the amino acid sequence set forth in SEQ ID NO:5 with or without at least one mutation selected from the group consisting of R38A, F42K and C125S, or SEQ ID NO:6.
7. The method of claim 6 , wherein the cancer is selected from the group consisting of melanoma, renal cell carcinoma, lung cancer and blood cancer.
8. The method of claim 6 , wherein the cytokine comprises the amino acid sequence set forth in SEQ ID NO:5 with at least one mutation selected from the group consisting of R38A, F42K and C125 S.
9. The method of claim 6 , wherein the cytokine comprises the amino acid sequence set forth in SEQ ID NO:6.
10. The method of claim 6 , wherein the anti-NKG2D receptor antibody comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs: 35 and 36; and SEQ ID NOs: 37 and 38.
11. The method of claim 6 , wherein the anti-NKG2D receptor antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, and SEQ ID NO: 42.